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Effects of Sotalol on the Signal-Averaged Electrocardiogram in 
Patients With Sustained Ventricular Tachycardia: Relation to 
Suppression of Inducibility and Changes in Tachycardia Cycle Length 
ROGER A. FREEDMAN, MD, FACC,* LABROS A. KARAGOUNIS, MD, FACC*t, 
JONATHAN S. STEINBERG, MD, FACC* 
Salt Lake City, Utah and New York, New York 
Objectives. This study examines the effects of sotalol on the 
signal-averaged electrocardiogram (ECG) in patients with spon-
taneous and inducible sustained \'entricular tachycardia and cor-
relates these findings with the effect of sotalol on tachycardia 
inducibility and tachycardia rate. 
Background. Standard electrocardiography generally does not 
detect any change in the duration of the QRS complex resulting 
from sotalol therapy. However, the signal-averaged ECG is more 
sensitive than the standard ECG for detecting changes in QRS 
duration induced by antiarrhythmic drugs and can also detect 
changes in late potential duration. 
Methods. Signal-averaged electrocardiography was performed 
before therapy in 30 patients with spontaneous and inducible ven-
tricular tachycardia, and both electrophysiologic study and a signal-
averaged ECG were repeated during therapy with d,l-sotalol. 
Sotalol is an investigational antiarrhythmic drug that is 
highly effective in suppressing reentrant ventricular tachy-
cardia in animal models (1,2) and has shown promise in 
patients with sustained ventricular tachycardia (3-10). Its 
antiarrhythmic efficacy is thought to result from its prolon-
gation of refractoriness and its minimal effect on conduction 
velocity in ventricular myocardium (1,3,4,11-14). Consistent 
with the latter effect is the observation that sotalol causes 
little or no prolongation of QRS duration as measured by the 
standard electrocardiogram (ECG) (3,4,7,15,16). 
The signal-averaged ECG is more sensitive than the 
standard ECG in detecting changes in QRS duration result-
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Results. During sotalol therapy the signal-averaged QRS du-
ration decreased by 2.6 ± 6.6 ms in the 11 patients with no 
inducible tachycardia during therapy, whereas it increased by 
3.8 ± 5.8 ms (p = 0.01) in the 19 patients with inducible 
tachycardia during therapy. In the latter group there was a 
significant posith'e correlation between prolongation of tachycar-
dia cycle length and prolongation of late potential duration by 
sotalol (r = 0.56, p = 0.01). 
Conclusions. Sotalol can alter QRS and late potential. dura-
tion as measured by the signal-averaged ECG. Prolongation 
of QRS duration or late potential duration may reflect a 
slowing of conduction by sotalol that may interfere with 
this agent's antiarrhythmic efficacy and slow ventricular tachy-
cardia. 
(J Am Coli CardioI1992;20:1213-9) 
ing from administration of antiarrhythmic drugs (17). Drug 
therapy that does not cause perceptible QRS prolongation on 
the standard ECG can result in QRS prolongation detectable 
by signal-averaged ECG. We have previously shown that 
prolongation of QRS and late potential duration by sodium 
channel blocking drugs correlates with prolongation of ven-
tricular tachycardia cycle length (17). In the present study, 
we examined the effects ofsotalol on QRS and late potential 
duration measured by the signal-averaged ECG and related 
these findings to suppression and slowing of iniluced ven-
tricular tachycardia. We hypothesized that any detectable 
prolongation of signal-averaged QRS or late potential dura-
tion resulting from sotalol therapy might reflect conduction 
slowing that could interfere with the drug's antiarrhythmic 
efficacy or contribute to prolongation of tachycardia cycle 
length. 
Methods 
Study patients. Thirty patients with inducible sustained 
ventricular tachycardia at baseline e1ectrophysiologic study 
who had a second electrophysiologic study during sotalol 
therapy underwent signal-averaged electrocardiography at 
baseline and during sotalol therapy. Table 1 summarizes the 
0735-10971921$5.00 
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Table 1. Demographic and Cardiac Data in 30 Study Patients 
Age (yr) 
Male patients 
Structural heart disease 
Coronary artery disease 
Hypertensive heart disease 
Idiopathic cardiomyopathy 
Left ventricular ejection fraction 
Bundle branch block or intraventricular 
conduction delay 
Clinical presentation 
Sustained ventricular tachycardia 
Ventricular fibrillation 
Syncope of unknown cause 
'Mean value:!: SD. 
n (%) 
63 :!: 10' 
27 (90) 
26 (87) 
3 (10) 
1 (3) 
0.36 :!: 0.16' 
12 (40) 
24 (80) 
3 (10) 
3 (10) 
demographic data, structural heart disease, left ventricular 
ejection fraction and clinical presentation of the 30 patients. 
Electrophysiologic study. Baseline electrophysiologic 
study was performed after administration of antiarrhythmic 
drugs had been discontinued for at least 5 half-lives of the 
drug and any of its active metabolites. Electrophysiologic 
study was performed according to a rigid stimulation se-
quence (18). The stimulus duration was 2 ms and current was 
twice diastolic threshold. The protocol for induction of 
ventricular arrhythmia began with pacing at the right ven-
tricular apex that used in sequence a single extrastimulus 
during sinus rhythm, two extrastimuli during sinus rhythm, 
one extrastimulus after ventricular drive and two extras tim-
uli after ventricular drive. The protocol then continued at the 
right ventricular outflow tract with one, two and three 
extrastimuli after ventricular drive. The final step in the 
sequence was three extrastimuli after ventricular drive at the 
right ventricular apex. The drive cycle lengths were 600, 500 
and 400 ms. Coupling intervals of extrastimuli were started 
at' 400 ms and were decreased in steps of 10 ms until 
refractoriness was reached. The coupling interval was kept 
at 10 ms above the refractory period when a subsequent 
extrastimulus was introduced. This stimulation protocol was 
followed until sustained (duration ~ 15 s) ventricular tachy-
cardia (rate ~ l00/min) or ventricular fibrillation was induced 
twice. 
The stimulation protocol used for the follow-up study was 
identical to that used for the baseline study. If ventncular 
arrhythmias had been induced with one or two extrastimuli 
during the baseline study, three extrastimuli were not used 
during the follow-up study. The end point of stimulation for 
the follow-up study was the induction of at least 15 beats of 
ventricular tachycardia (rate ~ lOO/min) or completion of the 
protocol (19). 
Tachycardia cycle length was measured by using hand-
held calipers from the recorded ventricular electrograms 
(100 mmls). When the tachycardia was irregular, the cycle 
lengths from lO consecutive cycles were averaged. When 
more than a single episode of tachycardia was induced, the 
cycle length used for data analysis was the average of the 
measured cycle lengths. 
The right ventricular effective refractory period was 
defined as the longest coupling interval of single extrastimuli 
delivered at the right ventricular apex after a basic drive of 
600 or 500 ms that did not result in ventricular depolariza-
tion. 
Signal·averaged electrocardiography. Baseline signal-
averaged ECGs were recorded at least 5 half-lives after the 
last dose of an antiarrhythmic drug and within 48 h of baseline 
electrophysiologic study. Follow-up signal-averaged ECGs 
were recorded at least 48 h after the start of the final dosing 
schedule of sotalol and within 24 h of the follow-up electro-
physiologic study. A Corazonix Predictor or an Arrhythmia 
Research Technology model 1200EPX was used for recordings 
and analysis. Three bipolar signals were simultaneously re-
corded and digitized at 2 kHz. The X lead was recorded 
between the left midaxillary line at the fifth intercostal space 
(positive) and the right midaxillary line at the fifth intercostal 
space (negative). The Y lead was recorded between the left 
anterior superior iliac spine (positive) and the suprasternal 
notch (negative). The Z lead was recorded between standard 
precordial lead V2 position (positive) and a position directly 
posterior to V2 (negative). Two hundred to 600 beats were 
averaged. Final noise levels (zero mean standard deviation of 
all three leads within a 5-ms window in the TP segment) were 
0.2 to 0.5 /LV. 
Averaged X, Y and Z recordings were filtered using a 
bidirectional four-pole Butterworth high pass digital filter 
with 40-Hz corner frequency (20). Filtered X, Y and Z 
recordings were combined into a single filtered QRS com-
plex according to the formula, (X2 + y2 + Z2)112. 
The onset and offset of the filtered QRS complex were 
determined automatically at the points where the signal 
exceeded three times the standard deviation of noise levels 
at the beginning and the end of the signal, respectively. The 
signal-averaged QRS duration was the difference between 
QRS onset and offset. The late potential duration was 
defined as the duration of the terminal filtered QRS complex 
not exceeding 40 /LV (20). The initial portion of the QRS 
complex was the portion of the QRS complex preceding the 
late potential. The terminal QRS amplitude was defined as 
the root-mean-square amplitude of the terminal 40 ms of the 
filtered QRS complex. For patients without bundle branch 
block or an intraventricular conduction defect, the signal-
averaged ECG was defined as showing a late potential if the 
signal-averaged QRS duration was > 120 ms, if the late 
potential duration was ~38 ms or if the terminal QRS 
amplitude was <20 /LV (20). For patients with bundle branch 
block or an intraventricular conduction defect on the stan-
dard ECG, a late potential was considered present if the 
signal-averaged QRS duration was ~145 ms, if the late 
potential duration was ~45 ms or if the terminal QRS 
amplitude was :517 ms (22). 
Standard electrocardiography. Standard ECGs were re-
corded within 24 h of the signal-averaged ECG at baseline 
FREEDMAN ET AL. 1215 JACC Vol. 20. No.5 
November 1. 1992:1213-9 SOTALOL AND SIGNAL-AVERAGED ELECTROCARDIOGRAM 
Table 2. Comparison of Standard and Signal-Averaged 
Electrocardiograms and Electrophysiologic Study Data at Baseline 
and During Sotalol Therapy 
Sotalol 
Baseline Therapy p Value 
Standard ECG 
Sinus cycle length 837:!: 183 1,120:!: 142 <0.0001 
QRS duration 117 :!: 21 119 :!: 23 0.03 
QT interval 409 :!: 45 510 :!: 58 <0.0001 
QTc interval 451 :!: 38 484 :!: 59 0.006 
Signal-averaged ECG 
QRS 143 :!: 22 145 :!: 23 NS 
LP 59:!: 20 59:!: 17 NS 
Initial QRS 84.4 :!: 22.7 85.7 :!: 23.9 NS 
RMS (Jl.V) 11.4 :!: 9.9 10.7 :!: 7.2 NS 
Late potentials (n [%]) 29 [97] 29 [97] 
Electrophysiologic study 
Right ventricular ERP 258:!: 30 314 :!: 36 <0.0001 
VT cycle length 274 :!: 58 332 :!: 61· <0.0001· 
·In 19 patients with persistent inducibility of ventricular tachycardia while 
receiving sotalol. Unless otherwise indicated all values are mean:!: SD and 
expressed in ms. ECG = electrocardiogram; ERP = effective refractory 
period; LP = late potential duration; RMS = terminal QRS root-mean-square 
amplitude; QTc = corrected QT interval; VT = ventricular tachycardia. 
and during sotalol therapy. Standard gain (10 mm/mY) and 
paper speed (25 mm/s) were used. The QRS duration and QT 
interval were determined visually and with hand-held cali-
pers to the nearest multiple of 10 ms. The corrected QT 
interval (QTc) was calculated by the Bazett formula as 
QT/(sinus cycle length in S)1I2. Bundle branch block or 
intraventricular conduction delay was considered present if 
the standard QRS duration was ~120 ms. 
Sotalol therapy. D,l-sotalol was provided in capsules by 
Bristol-Myers Squibb Company as part of ongoing clinical 
studies of the drug approved by the University of Utah 
Institutional Review Board on February 13, 1985, February 
II, 1987 and January 3, 1989. Informed consent was ob-
tained from each patient. Sotalol therapy was started at a 
dosage of approximately 3.5 mg/kg per day orally in two or 
three divided doses daily. The dose was increased after 48 h 
if tolerated. The maximal dose was 7.0 mg/kg per day. Serum 
samples for sotalol levels were drawn within 1 h before a 
scheduled dose during the final dosage regimen. 
Statistics. Values of continuous variables are expre~sed 
as mean value ± SD. A paired and unpaired Student t 
statistic was used to test for differences between continuous 
variables; the p value cited is for the two-tailed hypothesis. 
Pearson's r statistic was used to test correlations between 
continuous variables. A p value :50.05 was considered 
significant. 
Results 
Effects of sotalol on the standard ECG, signal-a\'eraged 
ECG and electrophysiologic data (Table 2). At baseline 
study, 29 (97%) of the 30 study patients had late potentials on 
the signal-averaged ECG. The QRS duration measured by 
signal-averaged ECG significantly exceeded that measured 
by standard ECG (mean difference 26.7 ± 20.2 ms, p < 
0.0001). 
The mean sotalol dose was 473 ± 128 mg/day. Trough 
serum levels of sotalol, obtained in 21 patients were 
2.0 ± 0.9 JLg/ml. As expected, sotalol significantly prolonged 
sinus cycle length (p < 0.0001), the QT (p < 0.0001) and QTc 
(p = 0.006) intervals and the right ventricular effective 
refractory period (p < 0.0001). Among all 30 patients, 
the mean values of signal-averaged QRS duration, late 
potential duration and terminal QRS amplitude were not 
significantly changed by sotalol. However, in individual 
patients sotalol resulted in changes ranging from -13.5 
to + 14.5 ms in signal-averaged QRS duration, from -17.0 to 
+ 13.0 ms in late potential duration and from -12.4 to 
+ 7.8 IL V in terminal QRS amplitude. In no patient did 
sotalol eliminate the late potential present on the base-
line signal-averaged ECG. 
The 12 patients with bundle branch block or intraventric-
ular conduction delay had a significantly longer signal-
averaged QRS duration at baseline (159 ± 20 ms) than did 
the other 18 patients (133 ± 17 ms) (p = 0.0005), but the two 
groups did not differ significantly in respect to baseline late 
potential duration (57 ± 24 vs. 60 ± 18 ms) or baseline 
terminal QRS amplitude (15 ± 13 vs. 9 ± 7 ILV). Changes in 
signal-averaged QRS duration and late potential duration 
resulting from sotalol therapy did not differ significantly 
between patients with and without bundle branch block or 
intraventricular conduction delay. There was no correlation 
between change in signal-averaged QRS duration resulting 
from sotalol and baseline signal-averaged QRS duration. 
However, there were significant negative correlations be-
tween changes in late potential duration and baseline late 
potential duration (r = -0.48, p = 0.006) and between 
changes in terminal QRS amplitude and baseline terminal 
QRS amplitUde (r = -0.75, p < 0.0001). 
There was a significant positive correlation between 
sotalol dose and prolongation of signal-averaged QRS dura-
tion (r = 0.40, p = 0.03) and a correlation of borderline 
statistical significance between sotalol serum level and pro-
longation of the signal-averaged QRS duration (r = 0.40, p = 
0.07) among the 21 patients with available serum sotalol 
levels. 
Correlation between sotalol's effects on tachycardia induc-
ibility and effects on signal.averaged ECG variables. Ventric-
ular tachycardia was not inducible during sotalol therapy in 
11 (37%) of the 30 patients. No variable from the baseline 
standard or signal-averaged ECG or baseline electrophysio-
logic study differed significantly between the II patients in 
whom tachycardia was rendered noninducible on sotalol 
therapy and the 19 patients in whom it remained inducible. 
Sotalol prevented induction of ventricular tachycardia in 3 
(25%) of the 12 patients with bundle branch block or intra-
ventricular conduction delay compared with 8 (44%) of the 
18 patients without these conditions (p = NS). 
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Figure 1. Top. Changes in signal-averaged QRS duration in 19 
patients in whom sotalol did not and II patients in whom it did 
prevent induction of ventricular tachycardia at electrophysiologic 
study. Bottom, Changes in late potential duration in the two groups 
of patients. Horizontal bars represent mean values. 
In the 11 patients in whom ventricular tachycardia was 
not inducible during sotalol therapy, there was a mean 
decrease of 2.6 ± 6.6 ms in signal-averaged QRS duration, 
whereas in the 19 patients in whom tachycardia remained 
inducible, there was a mean increase of 3.8 ± 5.8 ms (p = 
0.01). Similarly, there was a decrease in late potential 
duration of 2.8 ± 7.7 ms in the 11 patients in whom 
tachycardia was rendered noninducible compared with an 
increase of 2.0 ± 5.2 ms in the 19 patients with persistently 
inducible tachycardia (p = 0.04). Figure-l shows changes in 
signal-averaged QRS duration and late potential duration in 
these two patient groups. Changes in the duration of the 
initial portion of the QRS complex and in the terminal QRS 
amplitude did not differ between the two groups (Table 3). 
Figure 2 shows recordings from a patient in whom sotalol 
rendered tachycardia noninducible and shortened signal-
averaged QRS and late potential duration and from another 
patient in whom sotalol did not prevent tachycardia induc-
ibility and lengthened signal-averaged QRS and late potential 
duration. 
Changes resulting from sotalol in sinus cycle length, QRS 
duration determined from the standard ECG, QT and QTc 
intervals and right ventricular effective refractory period did 
Table 3. Changes in Signal-Averaged ECG, Standard ECG and 
Electrophysiologic Variables in Patients With and Without 
Inducible Ventricular Tachycardia (VT) During Sotalol Therapy 
VTNot 
VT Inducible Inducible 
(n = 19) (n = II) p Value 
Signal-averaged ECG 
I1QRS 3.8 ± 5.8 -2.6 ± 6.6 0.01 
I1LP 2.0 ± 5.2 -2.8 ± 7.7 0.04 
I1Initial QRS 1.8 ± 6.6 0.2 ± 5.9 NS 
I1RMS (p.V) -1.1 ± 4.3 -0.1 ± 4.9 NS 
Standard ECG 
I1Sinus cycte length 270 ± 198 303 ± 165 NS 
I1QRS duration 3.0 ± 5.2 2.1 ± 8.0 NS 
I1QT interval 99±66 102 ± 44 NS 
I1QTc interval 34 ± 73 30 ± 30 NS 
Electrophysiologic study 
I1Right ventricular ERP 55 ± 36 58 ± 31 NS 
All values are mean values ± SD and are expressed in ms unless otherwise 
indicated. 11 = change in; other abbreviations as in Table 2 . 
not differ between patients with and without suppression of 
tachycardia inducibility (Table 3). There was a difference of 
borderline statistical significance (p = 0.09) in serum sotalol 
levels between patients in whom tachycardia remained in-
ducible (2.3 ± 0.8 p,g/ml) and those in whom it was not 
inducible (1.6 ± 0.7 Ilg/ml). 
Correlation between sotalol's effects on tachycardia cycle 
length and its effects on signal-averaged ECG and ventricular 
refractoriness. In the 19 patients in whom ventricular tachy-
cardia remained inducible during sotalol therapy, the tachy-
cardia cycle length during therapy (333 ± 61 ms) was 
significantly prolonged compared with that at baseline 
(271 ± 60 ms, p < 0.00(1). There was a significant positive 
correlation (r = 0.56, p = 0.01) between prolongation of 
Figure 2. Signal-averaged electrocardiograms in two patients at 
baseline and during therapy with sotaloI. A, From a patient in whom 
sotalol prevented induction of ventricular tachycardia and resulted 
in shortening of signal-averaged QRS duration (expressed in ms). 
B, From a patient in whom sotalol did not prevent induction of 
ventricular tachycardia and resulted in prolongation of signal-
averaged QRS duration. 
A SOTALOL EFFECTIVE B SOTALOL INEFFECTIVE 
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Figure 3. Correlation between change in late potenti.al.duratio~ and 
prolongation in cycle length of ventricular tachycardl~ In 19 patle~ts 
with ventricular tachycardia induced both at baselIne and dunng 
sotalol therapy (r == 0.56, p == 0.01). 
tachycardia cycle length and prolongation of late potential 
duration by sotalol (Fig. 3), as well as a positive correlation 
between prolongation of tachycardia cycle length and pro-
longation of signal-averaged QRS duration that did not reach 
statistical significance (p = 0.12). The recordings in Figure 4 
are from a patient in whom sotalol resulted in a 96-ms 
prolongation in ventricular tachycardia cycle. length and 
large increases in late potential and signal-averaged QRS 
duration. 
There was no correlation between prolongation of tachy-
cardia cycle length and changes in sinus cycle length, QRS 
duration determined from standard ECG, QT and QTc 
intervals or the initial portion of the signal-averaged QRS 
complex. However, there was a significant correlation (r = 
0.51, p = 0.03) between prolongation in tachycardia cycle 
Figure 4. Signal-averaged electr?cardiograms an.d tracings of ven-
tricular tachycardia (VT) at baselIne (left) and dunng sotalol.therapy 
(right) in a patient in whom sotalol th.erapy resulted !n large 
increases in signal-averaged QRS duration, late potential (LP) 
duration and ventricular tachycardia cycle length (CL). All values 
are expressed in ms. 
BASELINE SOTALOL 
vrCL280 vrCL372 
trtffiYff{f(ffY 
length and of right ventricular effective refractory period by 
sotalo!. 
Discussion 
The principal findings of this study are that 1) sotalol can 
alter QRS and late potential duration as measured by signal-
averaged ECG; 2) sotalol causes less QRS prolongation and 
late potential duration in patients in whom it does than in 
patients in whom it does not prevent induction of tachyca~­
dia; and 3) among patients with ventricular tachycardia 
inducible during sotalol therapy, there is a positive correla-
tion between prolongation in tachycardia cycle length and 
prolongation of late potential duration resulting from sotalo!. 
Effect of sotalol on QRS and late potential duration. 
Several antiarrhythmic drugs have been shown to affect QRS 
and late potential duration as measured by signal-averaged 
ECG (17,23-25). The most frequently observed effect is 
prolongation of QRS and late potential duration by drugs 
known to prolong QRS duration on the standard ECG. 
However, shortening of QRS and late potential duration has 
occasionally been noted with these drugs (17,24). The signal-
averaged ECG is more sensitive than the standard ECG for 
detecting changes in QRS duration; and drugs generally not 
thought to prolong QRS duration, such as mexiletine, have 
occasionally been reported to alter the QRS and late poten-
tial duration on the signal-averaged ECG (17,26,27). 
Most clinical studies examining the effect of sotalol on 
QRS duration as measured by standard ECG and on infra-
His conduction time (HV interval) have reported no signifi-
cant change (3,4,7,8,15,16). However, one study (5) reported 
that sotalol induced a significant increase in HV interval, and 
two others (7,16) noted a trend toward prolongation ofQRS 
duration that did not reach statistical significance. In previ-
ous canine studies, sotalol has also been shown to cause 
dose-related prolongation in QRS duration as measured by 
standard (28) and signal-averaged (29) ECG. Among all 
patients in the present study, a small but statistically signif-
icant prolongation of mean QRS duration was observed on 
the standard ECG but not the signal-averaged ECG (Table 
3). This discrepancy may have been a result of a "rounding" 
error in the measurement of standard QRS duration, as this 
variable was measured to the nearest multiple of 10 ms. 
The variable effect of sotalol on signal-averaged QRS and 
late potential duration in the present study suggests that 
during sinus rhythm, sotalol may in some instances prolong 
conduction through diseased ventricular myocardium and in 
other instances block conduction through a portion of this 
tissue. Diseased, slowly conducting myocardium may be 
more vulnerable to conduction slowing or block by sotalol 
and other antiarrhythmic drugs because of altered cellular 
electrophysiology, abnormalities of cell to cell coupling or 
anatomic distortions (30-32). Cobbe et a!. (2) demonstrated 
that in chronically infarcted canine myocardium, sotalol can 
prolong fractionated epicardial electrograms and can result 
in greater prolongation of refractoriness than in normal 
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myocardium. In the present study, the negative correlation 
between baseline late potential duration and sotalol·induced 
change in this duration suggests that sotalol is more likely to 
block conduction when marked conduction delay is present 
at baseline and more likely to further prolong conduction 
time when more modest conduction delay is present at 
baseline. 
Relation between sotalol's effect on QRS duration and its 
antiarrhythmic efficacy. The antiarrhythmic efficacy of so-
talol is thought to result primarily from prolongation of 
refractoriness (3,4,11,12), and this agent's relatively high 
effectiveness in treating sustained ventricular arrhythmias is 
thought to be in part secondary to its minimal effect on 
conduction velocity (1,13,14). Any such slowing of conduc-
tion would interfere with sotalol's antiarrhythmic effect 
mediated through prolongation of the refractory period. In a 
canine model of atrial flutter, Feld et a!. (13) found evidence 
for slowing of conduction by sotalol and noted that dogs in 
which flutter was rendered noninducible had less conduction 
slowing than those in which atrial flutter continued to be 
inducible. It is possible that in the present study the greater 
prolongation in signal-averaged QRS duration induced by 
sotalol in patients with persistently inducible ventricular 
arrhythmias reflects a small decrease in conduction velocity 
in diseased tissue and that this effect on conduction inter-
feres with sotalol's antiarrhythmic efficacy. 
A relation between QRS widening and antiarrhythmic 
inefficacy has been reported for other drugs. Furukawa et a!. 
(33) found greater procainamide-induced prolongation of 
QRS duration on the standard ECG during ventricular 
pacing in patients in whom the drug did not than in those 
in whom it did prevent arrhythmia induction at electro-
physiologic study. Kus et a!. (34) reported a similar finding 
with propafenone. Hopson et a!. (35) found that type I 
antiarrhythmic drug therapy that did not prevent tachycardia 
induction was associated with greater prolongation of 
signal-averaged QRS duration than was therapy that did 
prevent it. 
Slowing of ventricular tachycardia by sotalol and relation 
to changes in the signal-averaged ECG. Sotalol has previ-
ously been reported (3-6,9,10) to slow the rate of induced 
ventricular tachycardia, to a degree similar to that observed 
in the present study. One explanation for this effect is 
that the tachycardia mechanism is "leading circle" reentry 
with no excitable gap (36), and that sotalol, by prolonging 
refractoriness and the impulse wavelength, lengthens the 
tachycardia circuit and prolongs revolution time without 
a change in conduction velocity. Another explanation is 
a direct effect of sotalol on conduction velocity. Studies 
examining the effect of sotalol on canine models of 
atrial flutter favor the latter explanation. In these canine 
models, an excitable gap during atrial flutter was not 
abolished by sotalol in doses that slowed the flutter rate 
(37,38), and sotalol slowed atrial conduction at pacing cycle 
lengths similar to the flutter cycle length (13,14). In the 
present study, prolongation of tachycardia cycle length 
correlated with prolongation of both late potential dura-
tion during sinus rhythm and right ventricular effective 
refractory period. These findings suggest that the effect of 
sotalol on conduction during tachycardia may result from 
both a direct effect on conduction and a prolongation of 
refractoriness. 
A correlation between prolongation of ventricular tachy-
cardia cycle length and late potential duration has been 
reported previously for other antiarrhythmic drugs (17). As 
in the present study, changes in cycle length correlated more 
strongly with changes in late potential duration than with 
changes in total signal-averaged QRS duration and not at all 
with changes in the duration of the initial portion of the 
signal-averaged QRS complex. These findings suggest that 
drug effect on slowly conducting myocardium generating the 
late potential may have the greatest effect on tachycardia 
cycle length. 
Limitations of the study. Changes in signal-averaged 
ECG variables were of smaller magnitude than those ob-
served with other drugs (17), and some portion of the 
changes could have been secondary to spontaneous variabil-
ity in signal-averaged ECG variables. Additional baseline 
signal-averaged ECGs after sotalol therapy was discontinued 
would have been of interest but were not obtained for 
logistic reasons. The sotalol used in this study was an equal 
mixture of d-sotalol and I-sotalo!. Whether the effects on the 
signal-averaged ECG observed in the present study are 
caused more by one isomer than the other is not known. This 
determination would require further studies using the sotalol 
isomers. 
We thank Allen W. Gomoll, MD, for providing the sotalol for the canine 
experiments and Judith L. Wintch for expert secretarial assistance. 
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